Long-term use of angiotensin-converting enzyme inhibitors protects against bone loss in African-American elderly men

Nahid Rianon, Catherine G. Ambrose, Hannah Pervin, Melissa Garcia, Scherezade K. Mama, Ann V. Schwartz, Brendan Lee, Tamara Harris

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Summary: Greater bone mineral density was observed after treating hypertension using angiotensin-converting enzyme inhibitor (ACEi). We report decreased rate of bone loss in hypertensive black men using ACEi for 9 years. There may be a gender- and race-specific effect of ACEi in the prevention of age-associated bone loss. Purpose: There is evidence of bone mass preservation in patients receiving ACEis, commonly used to treat hypertension. However, limitations of previous studies include being cross-sectional or only including a short-term follow-up of patients using ACEi and including patients with diabetes, which affects bone metabolism. None of the previous studies described effects of ACEi stratified by race. The objective of this study was to investigate differences in changes in bone mineral density (BMD) in older adults who suffer from hypertension and had reported ACEi use during each study visit for at least 9 years during the study, stratified by gender and race. Methods: We used data from the Dynamics of Health, Aging and Body Composition (HABC) study, which enrolled 3075 community-dwelling older white and black individuals. We compared changes in femoral neck, total hip, and whole-body BMD after either no use of ACEi (n = 580) or long-term use (at least 9 years) of ACEi (n = 239) in HABC participants with hypertension and no known diagnosis of diabetes mellitus. Results: Overall, BMD values significantly decreased for all subgroups over time. In the stratified multivariate analysis, long-term use of ACEi was associated with a reduced rate of decline for all three BMD measures among black men, but no significant effect was observed in the other subgroups. Conclusion: Our findings show a gender- and race-specific effect of ACEi in the prevention of age-associated bone loss that warrants further evaluation.

Original languageEnglish (US)
Article number94
JournalArchives of Osteoporosis
Volume12
Issue number1
DOIs
StatePublished - Dec 1 2017

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
African Americans
Bone and Bones
Bone Density
Hypertension
Body Composition
Independent Living
Femur Neck
Health
Hip
Diabetes Mellitus
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Orthopedics and Sports Medicine

Cite this

Rianon, Nahid ; Ambrose, Catherine G. ; Pervin, Hannah ; Garcia, Melissa ; Mama, Scherezade K. ; Schwartz, Ann V. ; Lee, Brendan ; Harris, Tamara. / Long-term use of angiotensin-converting enzyme inhibitors protects against bone loss in African-American elderly men. In: Archives of Osteoporosis. 2017 ; Vol. 12, No. 1.
@article{ea6d0d4489494884ad23bab8d14d2f11,
title = "Long-term use of angiotensin-converting enzyme inhibitors protects against bone loss in African-American elderly men",
abstract = "Summary: Greater bone mineral density was observed after treating hypertension using angiotensin-converting enzyme inhibitor (ACEi). We report decreased rate of bone loss in hypertensive black men using ACEi for 9 years. There may be a gender- and race-specific effect of ACEi in the prevention of age-associated bone loss. Purpose: There is evidence of bone mass preservation in patients receiving ACEis, commonly used to treat hypertension. However, limitations of previous studies include being cross-sectional or only including a short-term follow-up of patients using ACEi and including patients with diabetes, which affects bone metabolism. None of the previous studies described effects of ACEi stratified by race. The objective of this study was to investigate differences in changes in bone mineral density (BMD) in older adults who suffer from hypertension and had reported ACEi use during each study visit for at least 9 years during the study, stratified by gender and race. Methods: We used data from the Dynamics of Health, Aging and Body Composition (HABC) study, which enrolled 3075 community-dwelling older white and black individuals. We compared changes in femoral neck, total hip, and whole-body BMD after either no use of ACEi (n = 580) or long-term use (at least 9 years) of ACEi (n = 239) in HABC participants with hypertension and no known diagnosis of diabetes mellitus. Results: Overall, BMD values significantly decreased for all subgroups over time. In the stratified multivariate analysis, long-term use of ACEi was associated with a reduced rate of decline for all three BMD measures among black men, but no significant effect was observed in the other subgroups. Conclusion: Our findings show a gender- and race-specific effect of ACEi in the prevention of age-associated bone loss that warrants further evaluation.",
author = "Nahid Rianon and Ambrose, {Catherine G.} and Hannah Pervin and Melissa Garcia and Mama, {Scherezade K.} and Schwartz, {Ann V.} and Brendan Lee and Tamara Harris",
year = "2017",
month = "12",
day = "1",
doi = "10.1007/s11657-017-0387-3",
language = "English (US)",
volume = "12",
journal = "Archives of Osteoporosis",
issn = "1862-3522",
publisher = "Springer London",
number = "1",

}

Long-term use of angiotensin-converting enzyme inhibitors protects against bone loss in African-American elderly men. / Rianon, Nahid; Ambrose, Catherine G.; Pervin, Hannah; Garcia, Melissa; Mama, Scherezade K.; Schwartz, Ann V.; Lee, Brendan; Harris, Tamara.

In: Archives of Osteoporosis, Vol. 12, No. 1, 94, 01.12.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term use of angiotensin-converting enzyme inhibitors protects against bone loss in African-American elderly men

AU - Rianon, Nahid

AU - Ambrose, Catherine G.

AU - Pervin, Hannah

AU - Garcia, Melissa

AU - Mama, Scherezade K.

AU - Schwartz, Ann V.

AU - Lee, Brendan

AU - Harris, Tamara

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Summary: Greater bone mineral density was observed after treating hypertension using angiotensin-converting enzyme inhibitor (ACEi). We report decreased rate of bone loss in hypertensive black men using ACEi for 9 years. There may be a gender- and race-specific effect of ACEi in the prevention of age-associated bone loss. Purpose: There is evidence of bone mass preservation in patients receiving ACEis, commonly used to treat hypertension. However, limitations of previous studies include being cross-sectional or only including a short-term follow-up of patients using ACEi and including patients with diabetes, which affects bone metabolism. None of the previous studies described effects of ACEi stratified by race. The objective of this study was to investigate differences in changes in bone mineral density (BMD) in older adults who suffer from hypertension and had reported ACEi use during each study visit for at least 9 years during the study, stratified by gender and race. Methods: We used data from the Dynamics of Health, Aging and Body Composition (HABC) study, which enrolled 3075 community-dwelling older white and black individuals. We compared changes in femoral neck, total hip, and whole-body BMD after either no use of ACEi (n = 580) or long-term use (at least 9 years) of ACEi (n = 239) in HABC participants with hypertension and no known diagnosis of diabetes mellitus. Results: Overall, BMD values significantly decreased for all subgroups over time. In the stratified multivariate analysis, long-term use of ACEi was associated with a reduced rate of decline for all three BMD measures among black men, but no significant effect was observed in the other subgroups. Conclusion: Our findings show a gender- and race-specific effect of ACEi in the prevention of age-associated bone loss that warrants further evaluation.

AB - Summary: Greater bone mineral density was observed after treating hypertension using angiotensin-converting enzyme inhibitor (ACEi). We report decreased rate of bone loss in hypertensive black men using ACEi for 9 years. There may be a gender- and race-specific effect of ACEi in the prevention of age-associated bone loss. Purpose: There is evidence of bone mass preservation in patients receiving ACEis, commonly used to treat hypertension. However, limitations of previous studies include being cross-sectional or only including a short-term follow-up of patients using ACEi and including patients with diabetes, which affects bone metabolism. None of the previous studies described effects of ACEi stratified by race. The objective of this study was to investigate differences in changes in bone mineral density (BMD) in older adults who suffer from hypertension and had reported ACEi use during each study visit for at least 9 years during the study, stratified by gender and race. Methods: We used data from the Dynamics of Health, Aging and Body Composition (HABC) study, which enrolled 3075 community-dwelling older white and black individuals. We compared changes in femoral neck, total hip, and whole-body BMD after either no use of ACEi (n = 580) or long-term use (at least 9 years) of ACEi (n = 239) in HABC participants with hypertension and no known diagnosis of diabetes mellitus. Results: Overall, BMD values significantly decreased for all subgroups over time. In the stratified multivariate analysis, long-term use of ACEi was associated with a reduced rate of decline for all three BMD measures among black men, but no significant effect was observed in the other subgroups. Conclusion: Our findings show a gender- and race-specific effect of ACEi in the prevention of age-associated bone loss that warrants further evaluation.

UR - http://www.scopus.com/inward/record.url?scp=85032575962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032575962&partnerID=8YFLogxK

U2 - 10.1007/s11657-017-0387-3

DO - 10.1007/s11657-017-0387-3

M3 - Article

C2 - 29080997

AN - SCOPUS:85032575962

VL - 12

JO - Archives of Osteoporosis

JF - Archives of Osteoporosis

SN - 1862-3522

IS - 1

M1 - 94

ER -